Vor Biopharma
58 hedge funds and large institutions have $400M invested in Vor Biopharma in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 6 reducing their positions, and 5 closing their positions.
417% more call options, than puts
Call options by funds: $217K | Put options by funds: $42K
317% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 6
220% more capital invested
Capital invested by funds: $125M → $400M (+$275M)
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
21% more funds holding
Funds holding: 48 → 58 (+10)
3.64% more ownership
Funds ownership: 4.14% → 7.78% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$57.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.7M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$23.4M |
| 4 |
AG
Artal Group
Luxembourg
|
+$11.5M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$1.02M |
| 2 |
BlackRock
New York
|
-$991K |
| 3 |
E
Ergoteles
New York
|
-$210K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$103K |
| 5 |
Goldman Sachs
New York
|
-$76K |
VOR Hedge Fund Activity: Q4 2022 in Review
58 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2022, worth a combined $400M — up 220% from $125M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VOR positions and 5 closed out — a net gain of 10 holders — while 25 added to existing stakes and 6 trimmed.
The largest buyer was RA Capital Management, adding an estimated $57.5M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $1.02M sold.
- 58 institutional investors held Vor Biopharma (VOR) as of Q4 2022, up from 48 in Q3 2022.
- Funds reported $400M of Vor Biopharma stock for Q4 2022, up 220% quarter-over-quarter.
- 15 funds opened new Vor Biopharma positions in Q4 2022 and 5 closed out, a net change of +10 holders.
- The largest Vor Biopharma buyer in Q4 2022 was RA Capital Management, an estimated $57.5M added.
- The largest Vor Biopharma seller in Q4 2022 was Ally Bridge Group, an estimated $1.02M sold.
Based on aggregated 13F filings for Q4 2022.